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The role of natural idiotypic (Id-Abs) and anti-idiotypic (AId-Abs) autoantibodies against neuro-
antigens observed in different neurological disorders is not fully understood. In particular, limited
experimental evidence has been provided concerning the qualitative and quantitative serological
response after acute injuries of the central nervous system or during chronic mental diseases. In this
study, we analyzed the speciﬁc Id-Abs and AId-Abs serological reactivities against 4 neuro-antigens in
a large population of patients with ischemic stroke, schizophrenia, as well as healthy individuals.
Patients with ischemic strokewere tested at different time points following the acute stroke episode and
a correlation was attempted between autoantibodies response and different patterns of functional
recovery. Results showed variable and detectable Id-Abs and AId-Abs in different proportions of all
three populations of subjects. Among patients with different functional recovery after ischemic stroke,
a difference in time-related trends of Id-Abs and AId-Abs was encountered. Our observations suggest
thatchanges inthe production of natural neurotropic Abs may engender apositivehomeostatic, beside a
possible pathogenic effect, in speciﬁc neurological disorders.
Keywords: Natural autoantibodies; Idiotypic/anti-idiotypic antibodies; Ischemic stroke; Schizophrenia
INTRODUCTION
Almost a century ago, Vassily K. Khoroshko, a pioneer
researcher at Moscow University, performed the ﬁrst
experiments of immunization of dogs using brain
homogenates and studied the induced behavioral changes.
His observations led to the hypothesis that neurotoxic
antibodies could determine a number of mental and
neurological disorders (Khoroshko, 1912). Since then, the
links between neuropathology and immunopathology
have been widely studied but still remain poorly
understood. The reasons for this lack of progress are not
clear, possibly involving incorrect interpretations (likely
caused by excessive simpliﬁcation) of previously obtained
data or the skeptical disbelief of many scientists regarding
available evidence. In this paper, we attempt to address the
issue by illustrating our recent ﬁndings.
It is now accepted that the immune, nervous and
endocrine functions play integrated roles within the
human regulatory meta-system. Accordingly, disturbances
of any of the three components eventually lead to
compensatory changes in the activity of the others. As an
example, shifts in serum natural autoantibodies (auto-Abs)
against nervous cells proteins, such as neurotropic
idiotypic auto-Abs (Id-Abs) described in mental and
neurological diseases (Poletaev et al., 2000, 2002), have
been shown to be associated with shifts in anti-idiotypic
auto-Abs (AId-Abs). It is still unknown, however, if
changes in auto-Abs titers constitute a non-pathological
physiological response to an injurious insult or whether
they characterize the pathological process, possibly
worsening the disorder. Since Dr Khoroshko’s ﬁrst
ﬁndings, the presence of auto-Abs and increases in their
titers have been commonly considered signs of disease.
However, recent data showed the limits of such a
“classical” position indicating that natural auto-Abs
(including Id-Abs) can be physiological components of
the immune system, involved mainly in the regulation of
cell functions (Shoenfeld and Isenberg, 1992). For
example, the temporary rise of Id-Abs production/titers
following a neurological insult (such as a stroke)shouldbe
considered, at least in part, as a sign of recovery, rather
than a marker of disease progression. It is still poorly
understood, however, how individual immunological
changes, such as raised auto-Abs, relate to pathological
conditions and whether such changes may be considered
qualitatively and quantitatively adequate. In the ﬁrst
part of the present study, in an attempt to evaluate
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of speciﬁc Id-Abs and corresponding AId-Abs obtained
from rabbits immunized with the neurotropic protein
S100. We then extensively studied speciﬁc Id-Abs and
AId-Abs against 4 neural antigens (Ags) in a large
population of patients who suffered ischemic stroke (IS),
as well as patients affected by schizophrenic disorder
(SCH) and healthy subjects (HS) by using a new ELISA
protocol. A serological analysis of patients with IS was
also performed at different time points after the acute
episode and a correlation between auto-Abs response and
different patterns of functional recovery was attempted.
MATERIALS AND METHODS
Immunization of Rabbits
Cytoplasmic brain protein S100, cytoskeletal glial
ﬁbrillary acidic protein (GFAP), and 65-kDa brain cell
membrane protein MP65 were puriﬁed from bovine brain
as previously described (Poletaev et al., 2000). Nerve
growth factor (NGF) was purchased from Sigma–Aldrich
(Moscow, Russia). Adult female rabbits were injected
subcutaneously with 200mg of Ag biweekly for 6 weeks.
The Ags were suspended in 500ml of 0.14M NaCl and
carefully mixed with equal volume of Complete Freund
Adjuvant (Difco, Kansas City, MO, USA). Blood samples
were collected 1 week after the ﬁnal injection and sera was
obtained by centrifugation.
Evaluation of Anti-idiotypic Fab-fragments or
Native Ag for ELISA
The detection of Abs against native Ag or Ag-mimicking
AId-Fab-fragments was investigated through the evalu-
ation of S100 and S100-mimicking AId-Fab-fragments by
two different approaches.
First,96-wellimmunoplates(Nuncmaxisorp,Denmark)
were coated with either native S100 protein, S100-
mimicking AId-Fab-fragments obtained from rabbit
hyperimmune serum, bovine serum albumin (BSA) or
Fab-fragments of non-immune rabbit IgG (all at 3ug/ml
concentration in 0.1M carbonate buffer pH 9.5) overnight
at 48C. Plates were washed three times using PBS with
0.05% Tween (PBST), and 100ul of serum from
immunized rabbits (at serial dilutions) were added to
each well for 16h at 48C. O-phenylenediamin/H2O2 as
substrate was then added and the optical density (OD)
measured at 490nm. Second, 96-well immunoplates
(Nunc maxisorp) were coated with S100-mimicking
AId-Fab-fragments obtained from rabbit hyperimmune
serum as previously described and washed. To each well
wasthenaddedeitherS100protein(10ug)orBSA(10ug).
The plates were gently shaken for 3h at 378C, washed, and
addedwithincreasingdilutions(from1:100to1:12,800)of
anti-S100 rabbit antiserum. Plates were then analyzed as
described above, after the addition of substrate.
Enzyme Immunoassay (EIA) Test-System ELI-N-Test
EIA was performed as previously described (Poletaev
et al., 2003). S100, GFAP, MP-65 and NGF were used for
rabbits immunization as well as for coupling with CNBr-
Sepharose (Pharmacia Biotech, Uppsala, Sweden) for
afﬁnity puriﬁcation of serum polyclonal idiotypic Abs
(Id-Abs) against these Ags. Id-Abs were additionally
puriﬁed upon HiTrap Protein-G (Pharmacia Biotech), and
their Fab-fragments (Fab-S100, Fab-GFAP, Fab-MP65,
Fab-NGF) were obtained after pepsin hydrolysis. The
speciﬁc Fab-fragments obtained were immobilized upon
CNBr-Sepharose and used for separation of anti-idiotypic
Abs (AId-Abs) from the same portions of antisera which
were used to obtain Id-Abs. AId-Abs against idiotypic
Fab-S100, Fab-GFAP, Fab-MP65, Fab-NGF were puriﬁed
upon HiTrap Protein-G, passed through columns with
immobilized non-immune rabbit IgG, and Fab-fragments
of corresponding AId-Abs were prepared. Id-Fab-
fragments against S100, GFAP, MP65 and NGF, and
corresponding AId-Fab-fragments were used as the main
components of the test-system ELI-N-Test for detection of
appropriate AId-Abs and Id-Abs in serum samples.
Evaluation of Serum Immunoreactivity (IR)
Study of IR EIA was performed as previously described
(Poletaev et al., 2000, 2003). Brieﬂy, serum samples
were diluted 1:200 in 0.05% Tween 20PBS (PBST), and
96-well immunoplates (Nunc maxisorp) were coated
with Id- or AId-Fab-fragments. ELISA protocol followed
previous description (Poletaev et al., 2003) and IR of
each sample was calculated in conditional units (CU)
(Shoenfeld and Isenberg, 1992), using the following
formula:
IR ¼
R 2 xðFabÞ £ 100
R 2 stðFabÞ
2 100
where R 2 x(Fab) is the EIA OD of patients’ sera and
R 2 st(Fab) the OD of a known control serum. A highly
standardized sample of human immunoglobulins of IgG
class was used as control sample and evaluated in each
immunoplate in parallel with analyzed serum samples.
The Id–AId reactions ratio for each serum sample was
calculated as described (Poletaev et al., 2000, 2003) by the
following equation:
ðCU þ 100Þreactionwithanti–idiotpicFab
ðCU þ 100ÞreactionwithcorrespondingidiotpicFab
Normal values were considered between 235 and
40CU and between 0.7 and 1.3, respectively, as previously
described (Poletaev et al., 2000, 2002).
Subjects
We obtained clinical information and serum samples from
109 patients with recent history of cortical or sub cortical
IS, 38 patients with a diagnosis of SCH and 220HS.
A.B. POLETAEVet al. 152Patients with IS (63 females, age 65 ^ 4 years) were
enrolled among inpatients admitted at the Neurology
Department of the Russian State Medical University.
Based on functional recovery after the stroke and Barthel
Index (Mahoney and Barthel, 1965), patients were
subdivided in 4 groups: Group 1 ðn ¼ 36Þ included
patients with good functional recovery and Barthel score
between 100 and 85, Group 2 ðn ¼ 35Þ patients with
satisfactory recovery and Barthel score between 80 and
65, Group 3ðn ¼ 27Þ patients with unsatisfactory recovery
and Barthel score between 60 and 45 balls, and Group 4
ðn ¼ 11Þ patients deceased within 12 days from the IS
episode. Serum samples were obtained at 3–5, 10–14 and
21–35 days after stroke. Moreover, serum samples at 6–8
months were also obtained from 12 patients from Group 3
and 10 patients from Group 1.
Subjects affected by SCH (22 females, age 42 ^ 9
years) were enrolled among inpatients admitted at the
Karelian Republican Psychiatry Hospital (Director Dr
V.M. Zlunikin) for SCH of paranoid form during the acute
period and the diagnosis was based upon MMPI criteria
(Walters, 1983). Disease duration in this group of patients
ranged between 2 months and 5 years. Serum samples
were obtained before any acute medical treatment was
started.
HS (155 females, age 36 ^ 6 years) included
individuals without signs or symptoms of allergy, current
infection, or endocrine, mental or neurological disorders.
Statistical Analysis
The chi-square test and Mann–Whitney U-test were used
for the comparison of categorical and continuous
variables, respectively. All analysis were two-tailed and
a P value ,0.05 was considered statistically signiﬁcant.
RESULTS
Following rabbit immunization with S100 we assessed the
presence in sera of auto-Abs against S100 (Id-Abs), an
S100-mimicking Fab fragment (AId-Abs), BSA, and a
control IgG Fab fragment at serial dilutions (Table I(A)).
Id-Abs and AId-Abs titers were found to be signiﬁcantly
higher than what observed against control IgG at dilutions
as high as 1:800 for Id-Abs and 1:6400 for AId-Abs
(Table I(A)). Further, the absorption of sera with S100 but
not with BSA signiﬁcantly reduced AId-Abs reactivity
observed at all dilutions (Table I(B)).
The presence of Id-Abs and AId-Abs against S100,
GFAP, MP65 and NGF was investigated in sera obtained
from patients with IS ðn ¼ 109Þ or SCH ðn ¼ 38Þ; as well
as HS ðn ¼ 220Þ: Results were expressed in two different
forms: the absolute values obtained for Id-Abs or AId-Abs
reactivities (expressed in CU) and the ratio between such
values were analyzed.
Id-Abs and AId-Abs reactivities observed among HS
are shown in Table II. This group (Table II(A)) presented
similar IR values for Id-Abs and AId-Abs, as reﬂected by
Id/AId ratios within the normal range (1.1 ^ 0.2 for S100;
1.2 ^ 0.1 for GFAP; 1.0 ^ 0.1 for MP65; 1.1 ^ 0.1 for
NGF). However, when the percentage of subjects
presenting IR values outside the normal range was
examined (Table II(B)), a higher fraction of subjects
presented altered AId-Abs values, compared with Id-Abs,
against MP65 and NGF (5 vs. 1.8% and 5.7 vs. 3.5%,
respectively; P ¼ NS).
Among patients with SCH, normal values of IR against
the 4 Ags were encountered in 36–51% of patients, with
similar values for Id-Abs and AId-Abs and the most
frequent alterations encountered against GFAP
(Table III(A)). The Id-Abs/AId-Abs ratio was found to
be within normal range in only 29–57% of subjects, with
major alterations observed against GFAP (65% presented
a ratio below normal range) (Table III(B)). Altered values
of IR (i.e. outside the deﬁned normal range) against the 4
Ags were found more frequently among patients with
SCH compared to healthy subjects (49–64% in SCH vs.
1.8–5.7% in HS; P , 0:05). Similar results were obtained
for frequencies of abnormal Id-Abs/AId-Abs ratios
(46–74% in SCH vs. 2–8% in HS; P , 0:05). Combined
results showed that alterations in IR against any of the 4
Ags were found in 97% of patients with SCH (vs. 6%
among HS; P , 0:05) while combined alterations in
Id-Abs/AId-Abs ratio were also detected in 89.5% of
patients with SCH (vs. 11% among HS; P , 0:05).
TABLE I (A) IR of anti-S100 rabbit antiserum at increasing dilutions against S100, S100-mimicrying Fab-fragments of anti-idiotypic Abs, BSA and
Fab-fragments of non-immune IgG; (B) IR of anti-S100 rabbit antiserum at increasing dilutions against S100-mimicrying Fab-fragments of anti-
idiotypic Abs after adsorption with S100 and BSA (Values are expressed as mean ^ standard deviation OD)
(A) Antigen (B) Adsorbing agent
Antiserum dilution S100 AId-Fab S100 BSA Control IgG Fab S100 BSA
1:100 1.12 ^ 0.20 2.15 ^ 0.30 0.20 ^ 0.14 0.21 ^ 0.08 0.29 ^ 0.12 0.95 ^ 0.16
1:200 0.73 ^ 0.11 1.88 ^ 0.15 0.12 ^ 0.11 0.22 ^ 0.09 0.19 ^ 0.09 0.80 ^ 0.11
1:400 0.51 ^ 0.12 1.53 ^ 0.15 0.17 ^ 0.13 0.19 ^ 0.11 0.21 ^ 0.10 0.62 ^ 0.14
1:800 0.33 ^ 0.08 0.98 ^ 0.17 0.14 ^ 0.08 0.14 ^ 0.14 0.18 ^ 0.12 0.41 ^ 0.10
1:1.600 0.16 ^ 0.10 0.72 ^ 0.09 0.13 ^ 0.11 0.14 ^ 0.12 0.24 ^ 0.16 0.21 ^ 0.13
1:3.200 0.11 ^ 0.09 0.41 ^ 0.11 0.14 ^ 0.12 0.15 ^ 0.07 0.27 ^ 0.14 0.19 ^ 0.18
1:6.400 0.14 ^ 0.15 0.21 ^ 0.12 0.12 ^ 0.12 0.16 ^ 0.09 0.25 ^ 0.13 0.17 ^ 0.14
1:12.800 0.12 ^ 0.12 0.16 ^ 0.14 0.17 ^ 0.07 0.12 ^ 0.11 0.28 ^ 0.15 0.15 ^ 0.16
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were found in all 109 patients with IS, regardless of their
functional outcome against S100, GFAP and MP65 at all
examined time-points (P , 0:01 vs. HS for all Ags).
On the other hand, isolated alterations of Id-Abs/AId-Abs
ratios were encountered in 16% of patients with IS (vs.
11% amongHS; P ¼ NS). In the subgroup of patients with
IS resulting in post-stroke dementia examined after 6–8
months (previously included in Group 3), an increase in
Id-Abs/AId-Abs ratio was encountered in 6 cases (vs. 4
with decreased ratio; P ¼ NS).
Patients with IS were stratiﬁed in 4 groups according to
their functional outcome. At 3–5 days after IS, patients in
Groups 1 and 2 (better recovery) presented lower anti-
S100 Id-Abs compared to patients in Groups 3 and 4
(worse recovery) [IR median 27CU (range 226, þ84) vs.
44CU (25, þ156); P , 0:05], while showing higher
reactivities at 10–14 days [IR 36CU (210, þ107) vs.
10CU (254, þ46); P , 0:02] (Fig. 1). Similar data were
obtained for IR against other investigated Ids-Abs and
AIds-Abs (data not shown).
DISCUSSION
The ﬁnal stages of Ag processing invivo are accompanied
by the presentation of different epitopes which are derived
from the processing of speciﬁc proteins, as complexes
with major histocompatibility complex molecules. These
events lead to the production of several polyclonal Abs,
some of which unable to recognize the native Ag form,
largely due to sterical impediments (Poletaev et al., 2003).
Such phenomenon often leads to a reduced sensitivity of
the commonly used laboratory methods for the detection
of polyclonal Abs. Therefore, as Fab-fragments of AId-
Abs may mimic different Ag epitopes (Poletaev et al.,
2002, 2003), using such fragments instead of native Ag
may increase the sensitivity of immunological methods.
The results described herein obtained testing antiserum of
rabbits immunized S100 or the corresponding AId-Fab-
fragments seem to conﬁrm such hypothesis (Table I). Sera
from immunized rabbits presented stronger reactivity
against S100-mimicking AId-Fab-fragments than against
S100 protein (Table I(A)). Moreover, no reactivity was
TABLE II (A) Serum IR of 220 healthy individuals against Id and AId
antigens. Reactivities are expressed in OD values (mean ^ standard
deviation) and Id-Abs / AId-Abs ratios; (B) Percentages of healthy
subjects with abnormal IR values (normal values are considered between
235 and 40CU for IR, and between 0.7 and 1.3 for ratio)
(A) Id-Abs AId-Abs Id-Abs / AId-Abs ratio
S100 2.2 ^ 0.3 1.8 ^ 0.4 1.1 ^ 0.2
GFAP 6.4 ^ 0.6 6.0 ^ 0.7 1.2 ^ 0.1
MP65 1.2 ^ 0.5 0.8 ^ 0.2 1.0 ^ 0.1
NGF 0.2 ^ 0.4 0.3 ^ 0.2 1.1 ^ 0.1
(B) Id-Abs ,235
or .40CU (%)
AId-Abs ,235
or .40CU (%)
Id-Abs / AId-Abs
ratio ,0.7 or .1.3 (%)
S100 4.1 3.7 3
GFAP 4.1 4.8 8
MP65 1.8 5 2
NGF 3.5 5.7 7
TABLE III Fractions of patientswith SCH presentingaltered IR against
different antigens, expressed as CU values of Id-Abs and AId-Abs
(A) and Id-Abs / AId-Abs ratio (B) against each Ag
(A) IR (CU) Id-Abs AId-Abs
S100 ,235 22% 27%
235, 40 range 49% 42%
.40 29% 31%
GFAP ,235 25% 12%
235, 40 range 46% 36%
.40 29% 48%
MP65 ,235 7% 31%
235, 40 range 47% 42%
.40 46% 27%
NGF ,235 28% 21%
235, 40 range 51% 48%
.40 21% 31%
(B) Id-Abs/AId-Abs ratio
S100 ,0.7 25%
0.7, 1.3 range 54%
.1.3 21%
GFAP ,0.7 65%
0.7, 1.3 range 29%
.1.3 5%
MP65 ,0.7 33%
0.7, 1.3 range 57%
.1.3 9%
NGF ,0.7 20%
0.7, 1.3 range 53%
.1.3 26%
TABLE IV Id-Abs/Aid-Abs ratios in patients with good rehabilitation
after stroke and in patients with post-stroke dementia
Id-Abs/Aid-
Abs (S100)
Id-Abs/Aid-
Abs (GFAP)
Id-Abs/Aid-
Abs (MP65)
Id-Abs/Aid-
Abs (NGF)
Patients with post-stroke dementia
1 1.1 1.0 1.0 1.0
2 0.6 1.6 1.0 0.9
3 2.2 1.0 4.0 0.7
4 1.0 0.9 1.0 1.4
5 1.2 0.8 0.7 1.1
6 1.0 0.5 0.8 1.0
7 0.8 0.9 0.9 0.9
8 0.9 0.9 0.9 0.9
9 0.5 0.9 0.9 1.3
10 1.4 0.7 0.9 0.9
11 0.6 0.8 1.3 0.9
12 1.4 1.0 1.0 1.1
Patients with good post-stroke rehabilitation
1 1.2 1.1 1.3 1.0
2 0.9 1.0 0.8 1.0
3 1.1 1.2 1.1 1.0
4 0.8 1.0 0.9 0.8
5 1.1 0.9 1.0 0.9
6 0.9 1.1 1.0 1.1
7 1.2 1.0 1.3 1.2
8 1.0 1.2 1.1 0.8
9 1.1 1.0 1.2 0.7
10 1.1 1.2 1.0 1.2
Abnormal data are indicated by bold.
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rabbits (Table I(A)). Speciﬁcity of Abs binding was then
proven by the inhibition of reactivities observed when
S100, but not BSA, were added (Table I(B)). These
observations, therefore, were used to develop an Id-AId-
based test-system ELI-N-Test to detect neurotropic Id-
Abs as well as their AId counterparts in human serum
samples (Russian Patent in preparation; Certiﬁcate of
priority #2003131816, 30 October 2003).
A conﬁrmation that neurotropic auto-Abs may play a
physiological role was possibly found in the detectable
presence of Id-Abs against all investigated proteins as well
as AId-Abs (i.e. constitutively expressed natural neuro-
tropic Abs) in sera from all investigated healthy subjects
(HS group; Table II). For practical purposes, we estimated
the normal ranges for IR (in CU—see above) for each
antigen used and the ratio between CUs for each pairs of
Id-Abs and AId-Abs (between 235 and 40CU and
between 0.7 and 1.3, respectively). Our ﬁndings showed
that IR and ratio were within these ranges in over 95% of
HS and did not correlate with age or sex of the individuals
(data not shown), thus conﬁrming previous reports
(Poletaev et al., 2000, 2002). These observations seem
to indicate that optimal (physiological) levels of different
neurotropic auto-Abs are maintained within narrow limits
by powerful feedback mechanisms, thus suggesting a role
for these molecules in regulatory mechanisms.
A very different scenario was encountered among
patients with neurological disorders. In 97% of SCH and
100% of IS patients, in fact, abnormal changes of IR could
be detected against all or some of the investigated Ags. We
note that, for SCH, our results obtained with GFAP appear
to be compatible with previous reports indicating an
increased expression of this protein speciﬁc for the disease
(Johnston-Wilson et al., 2000). Interestingly, dynamic
changes were observed across serial sampling among
patients attributed to different groups according to the
functional outcome of the IS (Fig. 1). In all 4 groups, an
early elevation followed by a signiﬁcant decrease over
time was observed in anti-S100 Id-Abs levels. Similar
trends were also observed for other Id-Abs as well as for
all AId-Abs (data not shown). Different patterns of
changes in Id-Abs over time, however, were found among
patients with different outcomes. For example, patients
with better functional recovery after IS (Groups 1 and 2)
presented the highest levels of IR after 10–14 days from
FIGURE 1 Dynamic changes over time in serum IR (expressed in CU) of anti-S100 Id-Abs in patients with IS subdivided in 4 groups according to the
functional recovery (see text). Evaluations of IR were executed at 3–5 (column 1), 10–14 (column 2) and 21–35 (column 3) days after the IS episode.
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(Groups 3 and 4) presented an earlier peak (3–5 days)
with subsequent signiﬁcant decrease over time.
Our results once again raise the question if the observed
changes should only be regarded as signs of disease, as
commonly thought. Available evidence seems to suggest
the opposite, thus implying a possible compensatory
nature of the observed changes. A further question regards
the adequacy (in location, magnitude and timing) of such
reaction. The observations reported herein point towards a
possible role for Id-Abs in the physiological attempt
performed by the general network of constitutively
expressed natural a-Abs, named “Immunculus”, (Poletaev
and Osipenko, 2003) (which may be roughly deﬁned as
the internal “mould” of the optimal metabolic state as
reﬂected by the immune system), to compensate for the
neurological loss and to re-establish the pre-existing
balance, as indicated by the changes in “failure” scenarios.
Interestingly, however, data obtained in the subgroup of
patients in which serum was analyzed also at 6–8 months
after IS, representing the two extremities of the range of
functional recovery (previously represented by Groups 1
and 3), showed the presence of an abnormal Id-Abs/AId-
Abs ratio in a higher percentage among patients with poor
recovery resulting in post-stroke dementia (Table IV).
This observation could indicate a possible change in
immunospeciﬁcity of the IR, hence showing also a
qualitative shift accompanying more severe outcomes.
Interestingly, a similar alteration pattern in speciﬁcity
ratios was encountered in the vast majority of patients
with SCH (89.5%). In this population, moreover, other
peculiarities in neurotropic auto-Abs were found, with
isolated alterations, rather than generalized (as seen in IS),
found in 73% of sera. No speciﬁc correlation between
clinical features and Ag-speciﬁc neurotropic auto-Abs
patterns was found (data not shown), although the cross-
sectional nature of this part of the study should be taken
into account as a possible reason for such absence of
correlation.
Further, the ﬁndings described herein seem to indicate a
possible correlation between the adequacy of changes in
the neurotropic auto-Abs and the pathophysiology of
neurological disorders such as SCH or the different
degrees of functional recovery after IS. Such data also
seem to be in accordance with what shown during long
follow-up on newborns from mothers who suffered
massive herpetic and cytomegalovirus infection during
pregnancy (Poletaev et al., 2002). In 12–15% of such
cases newborns presented abnormal (either elevated or
prominently depressed) serum contents of different
neurotropic auto-Abs during several years after birth,
and more than 70% of them developed neurological or
mental problems. In particular, we showed a different
longitudinal pattern of serum reactivity in patients with
different functional recovery. We could once more
assume, therefore, that the different occurrence over
time of the peak neurotropic auto-Abs titers observed in
patients with good clinical recovery after stroke may
represent an adaptive reaction of the immune system
aimed to the compensation of the neurological insult and
the resulting rehabilitation. The mechanisms leading to
this phenomenon are poorly understood, but we can
suggest a role for the cell growth stimulation exerted by a
number of neurotropic auto-Abs (Shoenfeld and
Isenberg, 1992; Zaichik and Churilov, 2001; Asakura
et al., 1996).
In conclusion, we suggest that changes in production of
neurotropic auto-Abs may play a positive homeostatic role
in deﬁned cases, as well as possibly be pathognomonic, in
different neurological disorders, similarly to what
observed for other biologically active regulatory mole-
cules. It is impossible, with the present state of knowledge,
to rule out the possibility that neurotropic auto-Abs might
be mere epiphenomenon of other events. It seems clear,
however, that a better understanding of the dialectics of
neurotropic auto-Abs, now often regarded as a theoretical
matter, can potentially provide better tools in the diagnosis
and clinical management of neurological and mental
disorders and possibly indicate targets for new treatments.
Only overtaking the skepticism raised by these and
previous experimental data by a part of the scientiﬁc
community will allow a more objective and productive
evaluation of this important issue.
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